2018
Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases—An Overview of Imaging Studies
Peterson AC, Li CR. Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases—An Overview of Imaging Studies. Frontiers In Aging Neuroscience 2018, 10: 127. PMID: 29765316, PMCID: PMC5938376, DOI: 10.3389/fnagi.2018.00127.Peer-Reviewed Original ResearchNoradrenergic dysfunctionParkinson's diseaseAlzheimer's diseaseDefault mode networkMRI studiesImaging studiesPathogenesis of ADPostmortem anatomical studiesConventional therapeutic strategiesControl network activityStructural MRI studiesMagnetic resonance imagingFunctional MRI studyHuman imaging studiesLC degenerationCerebral cortexNoradrenergic projectionsDopaminergic neurotransmissionNoradrenergic systemTherapeutic strategiesMedication developmentFunctional alterationsCognitive declineCognitive impairmentDysfunction
2013
Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[11C]O-methylreboxetine
Li CS, Potenza MN, Lee DE, Planeta B, Gallezot JD, Labaree D, Henry S, Nabulsi N, Sinha R, Ding YS, Carson RE, Neumeister A. Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[11C]O-methylreboxetine. NeuroImage 2013, 86: 306-310. PMID: 24121204, PMCID: PMC3947246, DOI: 10.1016/j.neuroimage.2013.10.004.Peer-Reviewed Original ResearchConceptsBody mass indexMultilinear reference tissue model 2Norepinephrine transporterNoradrenergic dysfunctionObese individualsLean individualsStructural MR scansBPND valuesNorepinephrine transporter availabilityReference tissue model 2Positron emission tomography (PET) imagingEmission Tomography ImagingPositron emission tomographyBrain norepinephrine transportersNE clearanceMass indexRaphe nucleusLocus coeruleusSynaptic availabilityObese peopleTransporter availabilityOccipital cortexComparison subjectsHealthy individualsObesity